These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 22816126)

  • 21. Performance indicators for carrier-based DPIs: Carrier surface properties for capsule filling and API properties for in vitro aerosolisation.
    Faulhammer E; Zellnitz S; Wutscher T; Stranzinger S; Zimmer A; Paudel A
    Int J Pharm; 2018 Jan; 536(1):326-335. PubMed ID: 29217472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Powder filling into hard gelatine capsules on a tamp filling machine.
    Podczeck F; Newton JM
    Int J Pharm; 1999 Aug; 185(2):237-54. PubMed ID: 10460919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of dry powder inhalers.
    Chougule MB; Padhi BK; Jinturkar KA; Misra A
    Recent Pat Drug Deliv Formul; 2007; 1(1):11-21. PubMed ID: 19075871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations.
    Benque B; Khinast JG
    Eur J Pharm Sci; 2021 Jan; 156():105574. PubMed ID: 32980431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
    Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CFD-DEM investigation of the effects of aperture size for a capsule-based dry powder inhaler.
    Zhu Q; Kakhi M; Jayasundara C; Walenga R; Behara SRB; Chan HK; Yang R
    Int J Pharm; 2023 Nov; 647():123556. PubMed ID: 37890648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.
    Mitchell JP; Stein SW; Doub W; Goodey AP; Christopher JD; Patel RB; Tougas TP; Lyapustina S
    AAPS PharmSciTech; 2019 May; 20(5):206. PubMed ID: 31147791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of HPMC Inhalation-Grade Capsules and Their Effect on Aerosol Performance Using Budesonide and Rifampicin DPI Formulations.
    Ding L; Brunaugh AD; Thakkar R; Lee C; Zhao QJ; Kalafat J; Maniruzzaman M; Smyth HDC
    AAPS PharmSciTech; 2022 Jan; 23(1):52. PubMed ID: 35018574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary drug delivery by powder aerosols.
    Yang MY; Chan JG; Chan HK
    J Control Release; 2014 Nov; 193():228-40. PubMed ID: 24818765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SCF-engineered powders for delivery of budesonide from passive DPI devices.
    Lobo JM; Schiavone H; Palakodaty S; York P; Clark A; Tzannis ST
    J Pharm Sci; 2005 Oct; 94(10):2276-88. PubMed ID: 16136557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Orally inhaled drug performance testing for product development, registration, and quality control.
    Lastow O; Svensson M
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):401-7. PubMed ID: 25237712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications.
    Behara SR; Farkas DR; Hindle M; Longest PW
    Pharm Res; 2014 Feb; 31(2):360-72. PubMed ID: 23949304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
    Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tuning aerosol performance using the multibreath Orbital® dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry.
    Zhu B; Young PM; Ong HX; Crapper J; Flodin C; Qiao EL; Phillips G; Traini D
    J Pharm Sci; 2015 Jul; 104(7):2169-76. PubMed ID: 25931324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of Electrostatic Behavior of Dry Powder-Inhaled Model Formulations.
    Jetzer MW; Morrical BD
    J Pharm Sci; 2019 Sep; 108(9):2949-2963. PubMed ID: 31004652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.
    Walenga RL; Longest PW
    J Pharm Sci; 2016 Jan; 105(1):147-59. PubMed ID: 26852850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statistical tools and control of internal lubricant content of inhalation grade HPMC capsules during manufacture.
    Ayala G; Díez F; Gassó MT; Jones BE; Martín-Portugués R; Ramiro-Aparicio J
    Int J Pharm; 2016 Apr; 503(1-2):36-40. PubMed ID: 26899981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Closer to an 'ideal inhaler' with the Easyhaler: an innovative dry powder inhaler.
    Chrystyn H
    Clin Drug Investig; 2006; 26(4):175-83. PubMed ID: 17163249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.